Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial Meeting Abstract
| Authors: | Apolo, A. B.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; Gurney, H.; Kessler, E. R.; Retz, M.; George, S.; Escudier, B.; Zhang, J.; Simsek, B.; Scheffold, C.; Motzer, R. J.; Choueiri, T. K. |
| Abstract Title: | Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602301 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4553 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4553 -- Source: Wos |
